Nath Bio-Genes (India) Limited
NSE:NATHBIOGEN.NS
188.91 (INR) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 3,326.249 | 3,012.915 | 2,783.605 | 3,073.445 | 2,798.87 | 2,305.551 | 1,916.323 | 1,697.256 | 1,621.059 | 1,853.27 | 1,894.194 | 1,377.03 | 1,239.153 |
| Cost of Revenue
| 1,650.842 | 1,345.916 | 1,239.684 | 1,360.93 | 1,275.975 | 1,079.311 | 848.361 | 710.857 | 545.349 | 582.364 | 601.722 | 532.085 | 503.429 |
| Gross Profit
| 1,675.407 | 1,666.999 | 1,543.921 | 1,712.515 | 1,522.896 | 1,226.24 | 1,067.962 | 986.398 | 1,075.71 | 1,270.906 | 1,292.472 | 844.945 | 735.724 |
| Gross Profit Ratio
| 0.504 | 0.553 | 0.555 | 0.557 | 0.544 | 0.532 | 0.557 | 0.581 | 0.664 | 0.686 | 0.682 | 0.614 | 0.594 |
| Reseach & Development Expenses
| 112.763 | 93.713 | 88.852 | 91.541 | 91.031 | 25.696 | 78.787 | 86.744 | 111.167 | 122.294 | 106.323 | 90.694 | 71.904 |
| General & Administrative Expenses
| 279.395 | 54.162 | 66.009 | 50.918 | 50.796 | 56.213 | 58.082 | 39.992 | 40.643 | 29.656 | 72.948 | 55.977 | 45.123 |
| Selling & Marketing Expenses
| 930.007 | 707.777 | 198.149 | 212.005 | 241.395 | 178.101 | 119.051 | 103.544 | 139.997 | 142.378 | 650.08 | 397.067 | 365.806 |
| SG&A
| 1,209.402 | 707.777 | 264.158 | 262.923 | 292.19 | 234.315 | 177.134 | 143.536 | 180.64 | 172.034 | 723.029 | 453.044 | 410.929 |
| Other Expenses
| 6.266 | 5.604 | 0.973 | 0.7 | 0.417 | 0.46 | 0.435 | 5.38 | 4.775 | 4.627 | 170.44 | 141.692 | 130.867 |
| Operating Expenses
| 1,209.402 | 1,208.215 | 1,197.354 | 1,067.854 | 987.897 | 804.237 | 652.971 | 719.878 | 861.163 | 965.922 | 999.791 | 685.431 | 613.7 |
| Operating Income
| 466.005 | 457.336 | 345.697 | 643.363 | 533.651 | 419.917 | 414.991 | 167.534 | 214.547 | 304.983 | 255.129 | 122.961 | 90.75 |
| Operating Income Ratio
| 0.14 | 0.152 | 0.124 | 0.209 | 0.191 | 0.182 | 0.217 | 0.099 | 0.132 | 0.165 | 0.135 | 0.089 | 0.073 |
| Total Other Income Expenses Net
| -84.846 | -95.693 | -980.034 | -75.852 | -48.566 | -31.234 | -114.446 | -98.986 | -62.39 | -41.455 | -37.552 | -36.553 | -31.274 |
| Income Before Tax
| 381.159 | 363.18 | -633.9 | 567.511 | 485.085 | 388.683 | 300.545 | 167.534 | 152.157 | 263.529 | 255.129 | 122.961 | 90.75 |
| Income Before Tax Ratio
| 0.115 | 0.121 | -0.228 | 0.185 | 0.173 | 0.169 | 0.157 | 0.099 | 0.094 | 0.142 | 0.135 | 0.089 | 0.073 |
| Income Tax Expense
| 19.462 | 11.529 | 39.516 | 10.895 | -19.756 | 4.348 | 6.36 | 4.71 | 10.482 | 9.554 | 12.088 | 5.504 | -1.256 |
| Net Income
| 396.185 | 350.114 | -673.38 | 556.616 | 504.84 | 384.335 | 294.185 | 162.825 | 141.675 | 253.975 | 243.04 | 117.457 | 92.006 |
| Net Income Ratio
| 0.119 | 0.116 | -0.242 | 0.181 | 0.18 | 0.167 | 0.154 | 0.096 | 0.087 | 0.137 | 0.128 | 0.085 | 0.074 |
| EPS
| 21.34 | 18.42 | -35.43 | 29.29 | 26.57 | 20.22 | 17.83 | 10.17 | 8.85 | 15.87 | 15.19 | 0.73 | 5.75 |
| EPS Diluted
| 21.34 | 18.42 | -35.43 | 29.29 | 26.57 | 20.22 | 17.31 | 10.17 | 8.85 | 15.87 | 15.19 | 0.73 | 5.75 |
| EBITDA
| 498.617 | 494.511 | 384.683 | 674.784 | 562.065 | 452.693 | 424.65 | 296.425 | 251.798 | 349.021 | 339.297 | 204.555 | 182.855 |
| EBITDA Ratio
| 0.15 | 0.164 | 0.138 | 0.22 | 0.201 | 0.196 | 0.222 | 0.175 | 0.155 | 0.188 | 0.179 | 0.149 | 0.148 |